Immunai applies artificial intelligence to decode the human immune system and accelerate pharmaceutical drug discovery. The company has built AMICA, a single-cell database containing harmonized data from thousands of samples, which it claims is the world's largest immune-focused resource of its kind. This foundation supports an end-to-end platform that helps pharmaceutical and research partners make decisions across drug development, from target discovery and preclinical evaluation through to clinical trial optimization.
The company works with major pharmaceutical partners including AstraZeneca and Teva. Its technical approach combines single-cell and multiomics analysis with machine learning and bioinformatics to address challenges in immunology, immuno-oncology, and autoimmune disease research. The team draws expertise from immunologists, engineers, drug developers, and computer scientists, with founders from MIT and Harvard.
